| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0140-6736(03)12560-3 |
| P698 | PubMed publication ID | 12598136 |
| P2093 | author name string | Garret A FitzGerald | |
| P2860 | cites work | COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression | Q24536398 |
| Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients | Q24555072 | ||
| The productive conformation of arachidonic acid bound to prostaglandin synthase | Q27627094 | ||
| Cyclooxygenase inhibitors and the antiplatelet effects of aspirin | Q28191912 | ||
| Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study | Q28192227 | ||
| Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man | Q28366380 | ||
| Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides | Q28619497 | ||
| The coxibs, selective inhibitors of cyclooxygenase-2. | Q34086325 | ||
| Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects | Q36984424 | ||
| Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? | Q42778090 | ||
| Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women | Q73940124 | ||
| P433 | issue | 9357 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | aspirin | Q18216 |
| pharmacodynamics | Q725307 | ||
| P304 | page(s) | 542-4 | |
| P577 | publication date | 2003-02-15 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Parsing an enigma: the pharmacodynamics of aspirin resistance | |
| P478 | volume | 361 |
| Q37785123 | AJC Editor's Consensus: Selective and Nonselective Nonsteroidal Anti-Inflammatory Drugs and Cardiovascular Risk |
| Q34515584 | Adventures in vascular biology: a tale of two mediators |
| Q23724883 | An overview of clinical pharmacology of Ibuprofen |
| Q36160606 | Antiplatelet therapy in acute coronary syndromes: current agents and impact on patient outcomes |
| Q37695400 | Antithrombotic drugs for patients with ischaemic stroke and transient ischaemic attack to prevent recurrent major vascular events |
| Q37044230 | Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin? |
| Q45748874 | Aspirin discontinuation syndromes: clinical implications of basic research studies |
| Q28192102 | Aspirin induces platelet receptor shedding via ADAM17 (TACE) |
| Q28187611 | Aspirin resistance |
| Q37585451 | Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial |
| Q28166368 | Aspirin, ibuprofen, and mortality after myocardial infarction: retrospective cohort study |
| Q34282832 | COX-2 and beyond: Approaches to prostaglandin inhibition in human disease |
| Q34390050 | Clinical importance of aspirin and clopidogrel resistance |
| Q37591007 | Clinical pharmacology of antithrombotic drugs in coronary artery disease |
| Q35581260 | Cox-2 Selective Inhibitors and Bone |
| Q35196930 | Cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory drugs in the management of arthritis |
| Q64118728 | Disturbed homocysteine metabolism is associated with cancer |
| Q40700210 | Do NSAIDs inhibit the cardioprotective effects of ASA? |
| Q45872607 | Hyperhomocysteinemia in women with advanced breast cancer |
| Q38087384 | Identifying determinants of variability to tailor aspirin therapy |
| Q33678007 | Non-Steroidal Anti-Inflammatory Drugs: An Overview of Cardiovascular Risks |
| Q37521092 | Prostaglandin E(2) synthase inhibition as a therapeutic target |
| Q36173750 | Selective COX-2 inhibitors and risk of myocardial infarction |
| Q24794673 | The antithrombotic profile of aspirin. Aspirin resistance, or simply failure? |
| Q38249105 | Updates on NSAIDs in patients with and without coronary artery disease: pitfalls, interactions and cardiovascular outcomes |
Search more.